Skip Navigation


JAC Advance Access originally published online on October 26, 2006
Journal of Antimicrobial Chemotherapy 2006 58(6):1291-1294; doi:10.1093/jac/dkl401
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/6/1291    most recent
dkl401v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brandt, C. T.
Right arrow Articles by Østergaard, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brandt, C. T.
Right arrow Articles by Østergaard, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis

Christian T. Brandt1,*, Niels Frimodt-Møller1, Jens D. Lundgren2, Michael Pedersen3, Ian C. Skovsted1, Ian J. Rowland4 and Christian Østergaard1,5

1 National Center for Antimicrobials and Infection Control, Statens Serum Institut Artillerivej 5, 2300 Copenhagen S, Denmark 2 CHIP, Copenhagen University Hospital Hvidovre Kettegaard Allé 30, 2650 Hvidovre, Denmark 3 Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet 2100 Copenhagen, Denmark 4 Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre Kettegaard Allé 30, 2650 Hvidovre, Denmark 5 Department of Clinical Microbiology, Copenhagen University Hospital Herlev Herlev Ringvej, 2730 Herlev, Denmark

Received 30 May 2006; returned 19 July 2006; revised 6 September 2006; accepted 7 September 2006

*Corresponding author. Tel: +45-32-68-81-83/+45-22-91-44-49; Fax: +45-32-68-32-31; E-mail: ctb{at}ssi.dk

Objective: Bacteraemia concomitant with meningitis has been shown to greatly affect outcome. Consequently, the efficacy of serotype-specific anti-pneumococcal antiserum (APAS) was investigated in a rat model of pneumococcal meningitis.

Methods: Rats were infected with Streptococcus pneumoniae serotype 3. All rats received ceftriaxone starting 26 h post-infection. APAS was administered either at the time of infection or 26 h post-infection and effects were compared with rats treated with antibiotics only.

Results and conclusion: A significant clinical benefit was found when APAS was given at the time of infection whereas no effect was found when administered 26 h after infection. This work indicates that the clinical value of using APAS in pneumococcal meningitis may be limited.

Keywords: Experimental meningitis , pneumococcal anti-serum , sepsis , outcome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.